MedWatch

Analyst: Coloplast delivers a slight disappointment

A small disappointment in the development in emerging markets and an “easy” base for comparison that could have led to a better start to the year are the biggest headlines from Coloplast’s Q1 statement, says an analyst, who otherwise sees it as “a bit of a non-event”.

Foto: Coloplast / PR

The recently published Q1 financial statement from the Danish medtech company Coloplast is pretty much as could be expected, according to analyst Michael Friis Jørgensen from Alm. Brand Markets.

“There are no real surprises anywhere. Turnover is as expected, and Coloplast hangs on to the strong margins, as they have done for some time now. But it was completely as expected. So it is a bit of a non-event,” he tells Medwatch, adding:

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier